RainDance Technologies
Founded Year
2004Stage
Acquired | AcquiredTotal Raised
$146.65MAbout RainDance Technologies
RainDance Technologies is a life sciences company developing products that enable more accurate, reliable, cost-effective and early detection of disease and predisposition risk in order to improve human healthcare. The company is focused on better healthcare outcomes and lowering costs for the research, diagnosis, and treatment of cancers and inherited diseases. The company's RainStorm digital droplet technology powers next-generation sequencing and genetic testing systems that deliver superior performance, cost, interpretability, and ease of use. RainDance systems are used routinely in major academic research institutions, clinical genetics laboratories, and hospitals around the world. Based in Lexington, Massachusetts, the company supports customers through its international sales and service operations as well as a global network of distributors and commercial service providers. On January 16th, 2017, RainDance Technologies was acquired by Bio Rad. The terms of the transaction were not disclosed.
Loading...
Loading...
Expert Collections containing RainDance Technologies
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
RainDance Technologies is included in 2 Expert Collections, including Digital Health.
Digital Health
10,585 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
457 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
RainDance Technologies Patents
RainDance Technologies has filed 68 patents.
The 3 most popular patent topics include:
- biotechnology
- fluid dynamics
- microfluidics
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/20/2018 | 3/7/2023 | Fluid dynamics, Molecular biology, Biotechnology, Microfluidics, Nanotechnology | Grant |
Application Date | 8/20/2018 |
|---|---|
Grant Date | 3/7/2023 |
Title | |
Related Topics | Fluid dynamics, Molecular biology, Biotechnology, Microfluidics, Nanotechnology |
Status | Grant |
Latest RainDance Technologies News
Jun 29, 2023
VIENNA--(BUSINESS WIRE)--Ribbon Biolabs, the DNA synthesis company, today announced the appointment of Roopom Banerjee as Executive Chairman of its Board of Directors. He brings 25 years of strategy, operations, business development, financial advisory, and investment experience in early and late-stage life science companies to Ribbon Biolabs. Mr. Banerjee has held executive, management, and board positions at several US- and EU-based companies, including as CEO of RainDance Technologies, which
RainDance Technologies Frequently Asked Questions (FAQ)
When was RainDance Technologies founded?
RainDance Technologies was founded in 2004.
Where is RainDance Technologies's headquarters?
RainDance Technologies's headquarters is located at 749 Middlesex Turnpike, Billerica.
What is RainDance Technologies's latest funding round?
RainDance Technologies's latest funding round is Acquired.
How much did RainDance Technologies raise?
RainDance Technologies raised a total of $146.65M.
Who are the investors of RainDance Technologies?
Investors of RainDance Technologies include Bio-Rad Laboratories, Alloy Ventures, Mohr Davidow Ventures, Acadia Woods Partners, Quaker BioVentures and 9 more.
Who are RainDance Technologies's competitors?
Competitors of RainDance Technologies include Owlstone Medical and 4 more.
Loading...
Compare RainDance Technologies to Competitors
OncoTAB is a biotechnology company focused on improving the quality of cancer care. The company's main offering is a non-invasive blood test that aids in the detection of breast cancer in women with dense breast tissue. OncoTAB primarily serves the healthcare industry. It is based in Charlotte, North Carolina.
Freenome uses computational biology and machine learning techniques to detect cancer in its early and treatable stages. It detects cancer at an early stage through a routine blood draw and uses a proprietary algorithm method for systematized early detection. It was founded in 2014 and is based in South San Francisco, California.
Accuragen is a company focused on the development of cancer diagnostics technology in the healthcare sector. The company's main service is the development of liquid biopsy technology, which is a non-invasive alternative to tissue biopsy, used for DNA and RNA sequencing to determine a patient's optimal treatment plan. Accuragen primarily sells to the healthcare industry, specifically in the field of cancer treatment. It is based in Menlo Park, California.
CirculoGene Diagnostics is a molecular diagnostics company operating in the healthcare industry. The company offers a comprehensive blood-based approach to detecting clinically significant tumor DNA/RNA alterations, aiding oncologists in personalizing and monitoring patient treatment plans. Its services primarily cater to the healthcare and medical industry. CirculoGene Diagnostics was formerly known as CirculoGene Theranostics, LLC. It was founded in 2015 and is based in Birmingham, Alabama.
20/20 GeneSystems is a company focused on modernizing clinical lab testing, primarily in the healthcare and biotechnology sectors. The company offers diagnostic tests that aid in the fight against cancer and COVID-19, utilizing machine learning and real-world data to provide comprehensive testing services. Their main offerings include a blood test that combines the results of multiple cancer biomarker tests to calculate a probability score for different types of cancers, and a range of COVID-19 testing services. It is based in Rockville, Maryland.
Liquid Genomics monitors patient therapy via blood-based molecular testing. Blood based testing is used to detect and quantify cancer gene mutations with high sensitivity using Digital PCR and or Allele Specific Blocker PCR for blood or tissue.
Loading...